Surgical oncology company Onkos Surgical has partnered with medical device firm Insight Medical Systems to leverage augmented reality (AR) to help in the treatment of musculoskeletal oncology.
The partners intend to specifically investigate the applications of Insight Medical’s Augmented Reality Visualization and Information System (ARVIS). Their initial project is an evaluation of this technology in tumour surgery.
ARVIS features tracking and visualisation functionalities to enable the accurate and efficient execution of surgical plans.
The headset comes with a capability to project virtual models of a patient’s anatomy into the surgeon’s field of view during the medical procedure, enabling them to view anatomical structures present under the surface.
ARVIS can also project models of the implants or instruments in order to allow the surgeon to see their association with the out-of-sight anatomical structures.
The technology primarily displays important measurements such as the orientation and position of instruments and implants relative to the anatomy. This ability is expected to result in less invasive surgery, enhance outcomes and minimise risk for patients.
Onkos Surgical CEO and co-founder Patrick Treacy said: “Onkos Surgical is investing heavily in capabilities and technology to bring innovation to musculoskeletal oncology surgeons.
“Augmented reality technology has the potential of simplifying the complex and providing surgeons with input and feedback that may improve the precision of surgical planning and interoperative workflow.”
Treacy added that the ARVIS technology complements Onkos Precision Oncology solutions portfolio. The company aims to promote new solutions for surgical oncology and enhance cancer treatment.
Insight Medical Systems R&D vice-president Jonathan Nielsen said: “There is a great opportunity to improve precision and visualisation in these complex procedures, and Onkos is an ideal partner to jointly develop a system that complements their expertise in surgical planning and implant design.”